Fortis Healthcare (FORTIS) Stock Overview
Operates as a healthcare delivery service provider in India. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for FORTIS from our risk checks.
FORTIS Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Fortis Healthcare Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹968.65 |
| 52 Week High | ₹1,104.30 |
| 52 Week Low | ₹742.20 |
| Beta | 0.65 |
| 1 Month Change | 1.71% |
| 3 Month Change | 10.27% |
| 1 Year Change | 26.90% |
| 3 Year Change | 241.01% |
| 5 Year Change | 315.73% |
| Change since IPO | 867.20% |
Recent News & Updates
Analysis Article • May 27
Analyst Estimates: Here's What Brokers Think Of Fortis Healthcare Limited (NSE:FORTIS) After Its Full-Year Report
Last week saw the newest yearly earnings release from Fortis Healthcare Limited ( NSE:FORTIS ), an important milestone...
Narrative Update • May 23
FORTIS: Upcoming Board Decisions And Firm Margins Will Support Future Upside
Analysts have nudged their fair value estimate for Fortis Healthcare slightly higher from ₹1,075.24 to ₹1,076.61, reflecting updated assumptions on the discount rate, revenue growth, profit margin and future P/E that remain broadly in line with prior expectations. What's in the News Board meeting scheduled for May 22, 2026 at 09:35 Indian Standard Time to review and approve audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026 (Key Developments).Narrative Update • Apr 22
FORTIS: ESOP 2026 Scheme And Firm Margins Will Support Future Upside
Analysts have inched their price target for Fortis Healthcare slightly lower to about ₹1,075 from roughly ₹1,076, citing updated assumptions that balance a small adjustment in expected revenue growth with a modestly higher profit margin outlook and a nearly unchanged forward P/E of around 51x. What's in the News Fortis Healthcare has scheduled a Board Meeting on Feb 13, 2026, to consider and approve its unaudited standalone and consolidated financial results for the quarter and period ended Dec 31, 2025 (company filing).Narrative Update • Apr 08
FORTIS: ESOP 2026 Approval And Stable Margins Will Support Future Upside
Analysts have trimmed their price target for Fortis Healthcare slightly to about ₹1,076 from roughly ₹1,079. They attribute this to small adjustments to assumptions around fair value, revenue growth, profit margins and future P/E multiples.Narrative Update • Mar 25
FORTIS: Upcoming ESOP Approvals And Stable Margins Will Support Future Upside
Analysts have lifted their price target on Fortis Healthcare slightly, with fair value moving from about ₹1,072.71 to roughly ₹1,079.35, citing small adjustments to revenue growth, profit margin and forward P/E assumptions. What's in the News Board meeting scheduled for Feb 13, 2026 to consider and approve the unaudited standalone and consolidated financial results for the quarter and period ended Dec 31, 2025 (company filing).Recent updates
Analysis Article • May 27
Analyst Estimates: Here's What Brokers Think Of Fortis Healthcare Limited (NSE:FORTIS) After Its Full-Year Report
Last week saw the newest yearly earnings release from Fortis Healthcare Limited ( NSE:FORTIS ), an important milestone...Narrative Update • May 23
FORTIS: Upcoming Board Decisions And Firm Margins Will Support Future Upside
Analysts have nudged their fair value estimate for Fortis Healthcare slightly higher from ₹1,075.24 to ₹1,076.61, reflecting updated assumptions on the discount rate, revenue growth, profit margin and future P/E that remain broadly in line with prior expectations. What's in the News Board meeting scheduled for May 22, 2026 at 09:35 Indian Standard Time to review and approve audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026 (Key Developments).Narrative Update • Apr 22
FORTIS: ESOP 2026 Scheme And Firm Margins Will Support Future Upside
Analysts have inched their price target for Fortis Healthcare slightly lower to about ₹1,075 from roughly ₹1,076, citing updated assumptions that balance a small adjustment in expected revenue growth with a modestly higher profit margin outlook and a nearly unchanged forward P/E of around 51x. What's in the News Fortis Healthcare has scheduled a Board Meeting on Feb 13, 2026, to consider and approve its unaudited standalone and consolidated financial results for the quarter and period ended Dec 31, 2025 (company filing).Narrative Update • Apr 08
FORTIS: ESOP 2026 Approval And Stable Margins Will Support Future Upside
Analysts have trimmed their price target for Fortis Healthcare slightly to about ₹1,076 from roughly ₹1,079. They attribute this to small adjustments to assumptions around fair value, revenue growth, profit margins and future P/E multiples.Narrative Update • Mar 25
FORTIS: Upcoming ESOP Approvals And Stable Margins Will Support Future Upside
Analysts have lifted their price target on Fortis Healthcare slightly, with fair value moving from about ₹1,072.71 to roughly ₹1,079.35, citing small adjustments to revenue growth, profit margin and forward P/E assumptions. What's in the News Board meeting scheduled for Feb 13, 2026 to consider and approve the unaudited standalone and consolidated financial results for the quarter and period ended Dec 31, 2025 (company filing).Narrative Update • Mar 10
FORTIS: Governance Events And Stable Margins Will Support Future Upside
Analysts have kept their price target for Fortis Healthcare broadly unchanged at around ₹1,073. This reflects only marginal tweaks to underlying revenue growth, profit margin assumptions and the forward P/E multiple used in their models.Narrative Update • Feb 24
FORTIS: Governance Calendar And Margin Outlook Will Support Future Upside
Analysts have slightly increased their price target for Fortis Healthcare to ₹1,072.71 from ₹1,070.88, citing updated assumptions that incorporate modestly higher revenue growth, improved profit margins, and a lower future P/E multiple in their models. What's in the News A board meeting is scheduled for Feb 13, 2026 to consider and approve the unaudited standalone and consolidated financial results for the quarter and period ended Dec 31, 2025 (company filing).Analysis Article • Feb 18
Fortis Healthcare Limited Just Missed Earnings - But Analysts Have Updated Their Models
Fortis Healthcare Limited ( NSE:FORTIS ) came out with its quarterly results last week, and we wanted to see how the...Narrative Update • Feb 07
FORTIS: Steady Fair Value And Governance Steps Will Support Future Upside
Narrative Update: Fortis Healthcare Analyst Price Target Analysts have kept their fair value estimate for Fortis Healthcare steady at ₹1,070.88, with minor adjustments to the discount rate and future P/E assumptions. These changes reflect updated views on risk and earnings quality rather than any major shift in the core outlook.Analysis Article • Feb 01
Should You Be Adding Fortis Healthcare (NSE:FORTIS) To Your Watchlist Today?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Narrative Update • Jan 24
FORTIS: Open Offer Progress And Governance Moves Will Support Future Upside
Analysts have slightly raised their price target on Fortis Healthcare to ₹1,070.88 from ₹1,063.44. This change reflects updated assumptions around fair value, revenue growth, profit margins and future P/E estimates.Narrative Update • Jan 09
FORTIS: Open Offer And Governance Changes Will Support Future Upside
Analysts have nudged their fair value estimate for Fortis Healthcare to ₹1,063.44 from ₹1,056.75 as minor tweaks to long term revenue growth, profit margin assumptions and a slightly higher future P/E feed through their models. What's in the News Northern Tk Venture Pte Ltd completed the acquisition of a 0.0002% stake in Fortis Healthcare for ₹0.3 million on November 4, 2025, with Morgan Stanley India Company and multiple law firms involved in advising the parties.Analysis Article • Jan 01
Is Fortis Healthcare (NSE:FORTIS) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Narrative Update • Dec 15
FORTIS: Open Offer Progress Will Support Future Upside Despite Ongoing Litigation
Analysts have nudged their price target for Fortis Healthcare slightly higher from ₹1,054.25 to ₹1,056.75, citing marginal upgrades to long term revenue growth and profit margin assumptions while keeping the discount rate broadly unchanged. What's in the News Northern TK Venture Pte Ltd, an indirect wholly owned subsidiary of IHH Healthcare, has progressed its long pending open offer process to acquire a 26.1% stake in Fortis Healthcare for about INR 33.5 billion, following SEBI approval on October 1, 2025.Analysis Article • Dec 02
Why Investors Shouldn't Be Surprised By Fortis Healthcare Limited's (NSE:FORTIS) P/E
Fortis Healthcare Limited's ( NSE:FORTIS ) price-to-earnings (or "P/E") ratio of 67.4x might make it look like a strong...Narrative Update • Nov 27
FORTIS: Future Outlook Will Benefit From Stake Acquisition Despite Legal Challenges
Analysts have raised their price target for Fortis Healthcare from ₹1,023.56 to ₹1,054.25. This change reflects modest improvements in projected revenue growth, even though the outlook for profit margin is slightly lower.Analysis Article • Nov 14
Fortis Healthcare Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Shareholders might have noticed that Fortis Healthcare Limited ( NSE:FORTIS ) filed its second-quarter result this time...Narrative Update • Nov 13
FORTIS: Future Performance Will Balance Recent Acquisition And Legal Developments
Analysts have increased their price target for Fortis Healthcare from ₹983.07 to ₹1,023.56. They cite improved profit margin forecasts despite slightly lower revenue growth expectations.Analysis Article • Oct 14
Here's Why Fortis Healthcare (NSE:FORTIS) Has Caught The Eye Of Investors
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Analysis Article • Sep 10
Returns Are Gaining Momentum At Fortis Healthcare (NSE:FORTIS)
What are the early trends we should look for to identify a stock that could multiply in value over the long term...Analysis Article • Aug 26
Getting In Cheap On Fortis Healthcare Limited (NSE:FORTIS) Might Be Difficult
Fortis Healthcare Limited's ( NSE:FORTIS ) price-to-earnings (or "P/E") ratio of 79.5x might make it look like a strong...Analysis Article • Aug 09
Fortis Healthcare Limited Just Beat EPS By 23%: Here's What Analysts Think Will Happen Next
NSEI:FORTIS 1 Year Share Price vs Fair Value Explore Fortis Healthcare's Fair Values from the Community and select...Narrative Update • Aug 07
Expanding Capacity And Specialty Care Will Transform India's Healthcare Landscape
Driven by a notable upward revision in consensus revenue growth forecasts and a modest improvement in net profit margin, Fortis Healthcare’s analyst price target has increased from ₹829.27 to ₹879.27. What's in the News Fortis Healthcare to hold a board meeting to review unaudited Q1 FY26 results and consider changes affecting rights of debenture holders of its INR 15.5 billion listed debentures.Analysis Article • Jul 12
Do Fortis Healthcare's (NSE:FORTIS) Earnings Warrant Your Attention?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Analysis Article • Jun 26
Here's Why Fortis Healthcare (NSE:FORTIS) Can Manage Its Debt Responsibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
New Narrative • Dec 04
Digital Initiatives And Agilus Diagnostics' Margin Improvements To Drive Earnings Growth
Improved hospital occupancy and growth in key specialties could enhance revenue growth and profitability, with impacts on net margins.Shareholder Returns
| FORTIS | IN Healthcare | IN Market | |
|---|---|---|---|
| 7D | 4.3% | 1.7% | -0.8% |
| 1Y | 26.9% | 9.7% | -2.9% |
Return vs Industry: FORTIS exceeded the Indian Healthcare industry which returned 9.7% over the past year.
Return vs Market: FORTIS exceeded the Indian Market which returned -2.9% over the past year.
Price Volatility
| FORTIS volatility | |
|---|---|
| FORTIS Average Weekly Movement | 4.0% |
| Healthcare Industry Average Movement | 6.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in IN Market | 10.2% |
| 10% least volatile stocks in IN Market | 4.8% |
Stable Share Price: FORTIS has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: FORTIS's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 12,237 | Ashutosh Raghuvanshi | www.fortishealthcare.com |
Fortis Healthcare Limited operates as a healthcare delivery service provider in India. The company offers services in the areas of cardiac science, critical care, vascular surgery, dental science, dermatology, diabetology/endocrinology, emergency and trauma, geriatric medicine, liver transplant and hepatobiliary sciences, pain and palliative medicine, ENT, foetal medicine, gastroenterology and hepatology science, general surgery, and haematology areas. It also provides services in the areas of infertility medicine, internal medicine, mental health and behavioral science, nephrology, neuro surgery, neurointerventional radiology, neurology, obstetrics and gynaecology, oncology, ophthalmology, orthopedics, pediatrics, physiotherapy and rehabilitation, plastic and reconstructive surgery, pulmonology, radiology, organ transplant, rheumatology, thoracic surgery, transfusion medicine, urology, medical generics, endocrine surgery, and other support specialties, as well as treat infectious diseases.
Fortis Healthcare Limited Fundamentals Summary
| FORTIS fundamental statistics | |
|---|---|
| Market cap | ₹731.29b |
| Earnings (TTM) | ₹10.42b |
| Revenue (TTM) | ₹91.28b |
70.2x
P/E Ratio8.0x
P/S RatioIs FORTIS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FORTIS income statement (TTM) | |
|---|---|
| Revenue | ₹91.28b |
| Cost of Revenue | ₹53.35b |
| Gross Profit | ₹37.93b |
| Other Expenses | ₹27.51b |
| Earnings | ₹10.42b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 13.80 |
| Gross Margin | 41.55% |
| Net Profit Margin | 11.41% |
| Debt/Equity Ratio | 28.3% |
How did FORTIS perform over the long term?
See historical performance and comparisonDividends
0.1%
Current Dividend Yield7%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/07 04:35 |
| End of Day Share Price | 2026/06/05 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Fortis Healthcare Limited is covered by 32 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gaurav Chugh | 360 ONE Capital Market Private Limited |
| Gaurav Tinani | Ambit Capital |
| Pranav Chawla | Ambit Capital |